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Acute leukemias are the most prevalent neoplastic disorder among 
children. In these patients the leukemic cells or blasts have replaced 
normal hematopoietic cells in bone marrow and have spread to 
different extramedullary sites. Increased survival among leukemic 
patients in recent decades has led to diagnosing some previously 
less recognized complications among these patients. One of these 
morbidities is ophthalmic involvement. The presence of ophthalmic 
involvement among leukemia patients is associated with poor 
prognosis. Ophthalmic involvement is more common in patients 
with AML and in adult patients. Leukemia may involve any ocular 
tissue such as conjunctiva, sclera, cornea, anterior chamber, iris, 
lens, vitreous, retina, choroid and optic nerve. In this review, the 
ocular manifestations of leukemia have been discussed.
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Introduction
Acute leukemias are the most common 
malignant disorder among children 1 and are 
characterized by uncontrolled proliferation of 
immature neoplastic cells in bone marrow 1,2. 
Typically the leukemic cells or blasts have 
replaced normal hematopoietic cells in 
bone marrow and have spread to different 
extramedullary sites 3. According to the 
cell lineage which has been involved, acute 
leukemia can be divided to acute lymphoblastic 
leukemia (ALL), acute myelogenous leukemia 
(AML), acute mixed lineage leukemia 
(AMLL) and acute undifferentiated leukemia 
(AUL) 4. ALL accounts for about 70 % of all 
cases of childhood leukemia 5. The prognosis 
of childhood ALL is much better than adult 
ALL 6. Nowadays the event free survival of 
children with ALL has improved to 75-85% 7. 
These patients often present with anemia, 
leukocytosis or leukopenia, hepatomegaly, 
splenomegaly, thrombocytopenia and 
lymphadenopathy 8. Both lymphoid and 
myeloid neoplasms result from abnormalities 
in genes that control cellular proliferation, 
survival and differentiation 9. 
The hallmark of AML is abnormal proliferation 
and differentiation of myeloid precursors 10. 
The incidence of AML in children is much 
lower in comparison to ALL11. In recent 
years, in developed countries, intensive 
treatments including hematopoietic stem 
cell transplantation combined with effective 
supportive care has improved the survival rate 
of these patients to about 70 % in childhood 12.
Increased survival among leukemic 
patients has led to more recognition of 
some previously overlooked complications 
including ophthalmic involvement 13. 
Leukemia may affect different ocular tissues 
including conjunctiva, sclera, cornea, anterior 
chamber, iris, vitreous, retina, choroid, lens 
and optic nerve 14. The presence of ophthalmic 
involvement is associated with poor prognosis; 
therefore it is worthy to perform an ophthalmic 
evaluation at the time of diagnosis of acute 
leukemia in children and adults 15.
Ocular involvement in acute leukemia can be 
classified in two categories, direct infiltration by 
leukemic cells and indirect ocular involvement 
due to hematological abnormalities such 
as anemia, thrombocytopenia, blood 
hyperviscosity or immune suppression 13, 14. 
These alterations may lead to hemorrhage, 
infection or sometimes vascular occlusion 13,14. 
Rarely ocular involvement may be the first 
sign of leukemic relapse 16. Ophthalmic 
involvement is more common in AML and 
more prevalent in adults than in children 15,17. 
One of the poor prognostic factors in acute 
leukemia is central nervous system leukemia, 
which can be diagnosed using cerebrospinal 
fluid exam 14, 18. The most common symptoms 
of ocular involvement in central nervous 
system leukemia include diplopia, blurred 
vision, extra-ocular muscle palsy and optic 
nerve edema 14. In this review, ophthalmic 
manifestations of acute leukemia are  discussed.
Pathophysiology
The ocular manifestations of acute leukemia 
can be divided into two groups 19. In the 
primary group, direct infiltration of neoplastic 
cells in different eye tissues leads to the ocular 
manifestations 19. In the secondary group, 
indirect causes such as ophthalmic injuries 
due to chemotherapy could be observed 19. For 
example immunosuppressive drugs can cause 
opportunistic infections 20. Direct leukemic 
infiltration can involve orbit, anterior segment, 
uvea and the optic nerve 21. Consequently 
papilledema, cranial nerve palsies or proptosis 
may be observed. Indirect ocular involvement 
in the majority of cases causes retinal, 
Hashemieh et al. Ophthalmic Manifestations of Acute Leukemia
Journal of Ophthalmic and Optometric Sciences. Volume 3, Number 1, Winter 2019
This work is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)
22
pre-retinal and vitreous hemorrhage 15. 
Sometimes indirect ophthalmic manifestations 
occur due to infection in different ocular 
structures and cause retinal venous occlusion 22.
Ocular toxicity of chemotherapeutic agents
Several chemotherapeutic agents used in 
treatment of acute leukemia can affect 
patients’ vision 23. The use of high dose 
glucocorticoids, especially in induction phase 
of acute lymphoblastic leukemia may result 
in increased intraocular pressure, cataracts, 
glaucoma, dry eye, diplopia and even 
blindness 24. Vincristine is a chemotherapeutic 
agent which is widely used in treatment 
protocols for ALL. Vincristine can affect motor 
nerves of the eye (Cranial nerve III, IV, VI and 
VII) 25, 26. Also this drug causes optic atrophy 26. 
Vinblastine has the same effects and both of 
these drugs may lead to corneal hypoesthesia 27. 
Methotrexate is another drug which has been 
used extensively in ALL, as oral, intravenous 
and intrathecal forms 28. Methotrexate can 
cause inter-nuclear ophthalmoplegia and 
optic neuropathy 29, 30. Cytosine arabinoside 
is another chemotropic drug which has some 
toxicity on corneal epithelium 31. The retinal 
toxicity of this drug has often been reported 
with high dose usage and is irreversible in 
majority of cases 32. Steroid eye drops have 
been used in order to prevent corneal toxicity 
in chemotherapeutic regimes with high dose 
cytosine arabinoside 33.Cyclosporine is the 
main drug for prevention of graft versus host 
disease in recipients of hematopoietic stem 
cell transplantation 34. Cyclosporine can cause 
posterior leukoencephalopathy syndrome 35. 
The clinical manifestations of this syndrome 
include headache, convulsion, change in 
mental condition and even blindness 36. 
Fortunately these presentations can disappear 
after discontinuation of cyclosporine 36.
Busulfan can cause posterior subcapsular 
cataracts 37. Fludarabine might lead to visual 
disturbances including progressive visual 
loss with anterior uveitis, blurred vision, 
vitritis, retinal vasculitis, visual field deficits, 
optic neuritis, and peripheral retinal necrotic 
lesions 38. Imatinib is a monoclonal antibody 
against B-lymphocyte antigen CD20 and may 
lead to periorbital edema, blurred vision and 
conjunctival hemorrhage 39-41.
Ophthalmic manifestations of acute 
leukemia
Ophthalmic and orbital lesions are the third 
most common extramedullary involvement 
in acute leukemias after the meninges and 
testicles involvement 13. In some patients, the 
ocular manifestations of leukemia occur earlier 
than systemic presentations of hematopoietic 
malignancy 14. The ophthalmic signs of 
leukemia often disappear after the successful 
chemotherapy and remission of disease but 
may reappear after the relapse of leukemia 42. 
Also the ocular finding of leukemia occur 
more commonly in the posterior segment in 
comparison to anterior segment 15. The most 
observed findings in the posterior segment 
include pre-retinal hemorrhage, intra-retinal 
hemorrhage and retinal hemorrhage with Roth 
spots 15. Retinal findings are the most prevalent 
ophthalmic manifestation in leukemia and 
retinal hemorrhage is the most common 
presentation 13, 14, 43. There is a strong association 
between ocular involvement and leukocyte or 
platelet count in leukemia 19. Lower platelet 
count and higher white blood cell count have 
been correlated with increased incidence 
of ophthalmic manifestations in leukemic 
patients 42, 44. Leukemic manifestations of 
various eye structures are discussed below in 
more detail.
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Conjunctiva
Conjunctiva is a rare site for leukemic 
involvement. Conjunctival lesions are more 
common in lymphocytic leukemia 14. Comma 
shaped venous abnormalities may be observed 
in conjunctiva which are caused by blood 
hyperviscosity 13, 14. Conjunctival tumors both 
in ALL and AML have rarely been reported 45. 
Also leukemic patients with thrombocytopenia 
and subconjunctival hemorrhage have been 
reported in multiple studies 15, 17, 43, 46, 47. 
Cornea 
Since cornea is an avascular structure so 
its involvement is not a common finding in 
leukemia 14. Peripheral corneal ulceration, 
pannus and sterile ring ulcers are some 
corneal manifestations in leukemia 13, 14, 48. 
Keratitis among leukemia patients has been 
observed due to immunosuppression or graft 
versus host disease 14. Graft versus host 
disease may also cause corneal thinning and 
consequently corneal perforation in recipients 
of hematopoietic stem cell transplantation 49. 
Iris and anterior segment
The characteristic finding of iris infiltration 
caused by acute leukemia is a change in iris 
color and a gray or yellow pseudohypopyon 20. 
Infiltration  of iris  often occurs  with 
involvement of choroid and ciliary body 20. 
Sometimes the signs and symptoms of acute 
glaucoma appear as the intraocular pressure 
(IOP) is also increased due to infiltration of 
trabecular meshwork 20. Another presentation 
of acute leukemia is spontaneous hyphema 50. 
Acute extramedullary relapse of acute 
leukemia can present as hypopyon uveitis 51. 
Occasionally primary relapse of acute leukemia 
involves anterior chamber segment 14. 
Choroidal involvement
Although in histologic evaluation of patients 
with acute leukemia choroid is more 
involved than retina the number of clinical 
retinal involvements is higher 14. Unilateral 
or bilateral uveitis, choroidal perivascular 
infiltration, patchy or diffuse choroiditis, 
choroidal thickening up to manifold 
(especially in macular area), retinal pigment 
epithelium hypertrophy or atrophy, and 
resultant photoreceptor destruction might also 
be observed 14, 19, 52. Also choroidal ischemia 
due to choriocapillary involvement and serous 
retinal detachment may occur 42, 43. 
Vitreo -retinal involvement
Retina is the most frequent tissue in acute 
leukemic ocular involvement and accounts 
for about 75 % of all ocular involvements 53,54. 
Sub-retinal, intra-retinal and pre-retinal 
hemorrhages especially in the macular area 
might appear with thrombocytopenia as the 
main cause 55. They may be flame shape or spot 
like with a white area at the center caused by 
the leukemic cells infiltration (Roth spots) 44. 
Other retinal features in acute leukemia 
are vessel dilation, tortuosity and venous 
aneurism at the peripheral parts of the retina 
due to blood hyperviscosity 44. Occasionally 
retinal vascular sheating may occur due to 
direct neoplastic cell infiltration 44. Retinal 
detachment, unilateral or bilateral retinitis, 
retinal masses and subretinal hypopyon have 
also been reported 56. These retinal masses 
and infiltrations usually disappear after 
chemotherapy 14, 42, 52. Blurred vision in retinal 
involvement is not usual except in macular 
involvement or blood penetration to vitreous 17. 
Cotton wool spot is seen due to ischemic 
effects of vascular involvement 14. 
Vitreous involvement is not common since the 
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internal limiting membrane is a barrier like 
structure which restricts the passage of cells 
to the vitreous 14.   
In addition to these findings bacterial or 
fungal endophthalmitis is reported due to 
immune deficiency caused by leukemia itself 
or its treatments 52. Other than to infiltrative 
retinitis there are some opportunist germs 
such as cytomegalovirus, herpes simplex 
and herpes zoster viruses which might cause 
infectious retinitis and occasionally retinal 
necrosis 51, 57, 58. Aspergillus and candida 
might also cause retinitis and vitritis in acute 
leukemia 58, 59. 
It should be noted that chorioretinal 
involvements of acute leukemia most often 
appear at the end stages of the disease and 
should alert us about leukemia progression 42.
Optic nerve and other cranial nerves 
involvement
Optic nerve involvement in acute leukemia 
presents with blurred vision and is visible in 
funduscopy as optic disc edema due to direct 
leukemic cells infiltration or papilledema due 
to rising intra cranial pressure 60.  Radiotherapy 
might arrest the progressive vision loss, but 
usually the lost vision will not return 61, 62. 
CT scan shows optic nerve enlargement due 
to meningeal thickening 63. Optic atrophy 
following long term disc edema can be 
confirmed with peripapillary OCT (optical 
coherence tomography) 59, 64. 
Cranial nerves involvement might cause 
diplopia and eye deviation 65. Some 
chemotherapeutic medications such as 
vincristine can cause cranial nerves palsy 
and resultant lid movement deficit or ocular 
motility insufficiency 66.
Orbital involvement
Orbital involvement due to acute leukemia is 
not common. Proptosis is the most frequent 
feature of orbital involvement. Eye movement 
limitation, optic disc edema and orbital venous 
dilation due to pressure effect are some other 
orbital findings among patients with acute 
leukemia 13, 67. 
Orbital CT scan usually shows diffuse, local or 
abscess like infiltrations especially in superior 
and superotemporal sites and pressure 
effects could be also observed 59, 68. The other 
symptoms might be pain, eyelid edema or 
discoloration towards red or blue, and lid 
ptosis 69.
Lacrimal gland is an important part of orbital 
cavity that may be involved in acute leukemia 
leading to its enlargement and resultant glob 
deviation towards inferonasal 70. Lacrimal 
gland atrophy and dry eye might appear in the 
long-term involvement 71. This complication 
might also be caused by treatment modalities 
such as chemotherapy or radiotherapy 52. 
Orbital masses due to AML are called 
granulocytic sarcoma 72. In addition to 
leukemic orbital masses there are some reports 
of palpable masses at the superotemporal site 
of orbit 46. In some cases of AML the orbital 
findings appear prior to other leukemia 
symptoms and their histological results 
confirm the leukemia sooner than getting 
a positive bone marrow biopsy or blood 
smear  46, 73.
In CT scan evaluation, well - defined 
homogenous isodense masses that occasionally 
penetrate into paranasal sinuses might be 
observed 46, 67. T1 weighted mode MRI might 
show isointense and T2 weighted MRI might 
indicate hyperintense masses. In the case of 
gadolinium injection mild enhancement of the 
lesion might be observed 46.
Horner syndrome has been observed due 
to cranial  nerve  involvement as a rare 
presentation of acute leukemia 74. Differential 
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diagnosis of leukemic orbital lesions 
are lymphoma, rhabdomyosarcoma, and 
neuroblastoma 46.
Discussion
In the initial description of ocular involvement 
in acute leukemia it was described as leukemic 
retinopathy in the 1860s, but nowadays we 
know that nearly all eye structures may be 
affected in leukemia 42. Ocular involvement 
among leukemic patients has been reported in 
various parts of the eye and orbit 14. The reported 
prevalence of these ocular involvements 
shows a wide variation in different studies. 
This might be caused by different stages of 
disease among patients entering different 
studies or the study design. Global and ocular 
involvements are more common in AML 
than ALL 13. Also ocular involvements are 
more prevalent in adults with leukemia in 
comparison with children 13.  The importance 
of regular ophthalmic examination at least 
every 6 months among patients with acute 
leukemia is clear especially when considering 
the close relation of ocular and central nervous 
system involvement 13.  
Management of ocular manifestations of acute 
leukemia is dependent on these regular eye 
exams and a close cooperation between the 
hematologists and ophthalmologists caring for 
these patients. It should be noted that some 
ocular manifestations among patients with 
acute leukemia are the result of therapies used 
in these patients. There should be a careful 
evaluation of these therapies harm and benefit 
before considering their termination. Future 
advances in diagnostic modalities might lead 
to early detection of ocular complications 
of acute leukemia and reduce the chance of 
irreversible vision loss among patients. 
Conclusion
Ocular involvement in acute leukemia can 
be caused by direct infiltration by leukemic 
cells or indirect ocular involvement due to 
hematological abnormalities such as anemia, 
thrombocytopenia, blood hyperviscosity 
or immune suppression. It might also bee 
caused by chemotherapeutic drugs used to 
treat leukemia. Regular eye exams and a close 
cooperation between the hematologists and 
ophthalmologists caring for these patients are 
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